div class=ts-pagebuttonPage 1button div class=ts-image a href=https:reader039vdocumentecomreader039viewer20220331225e31638c7f7a9b00971bd473html5page1jpg target=_blank amp-img class=ts-thumb alt=Page 1: romvacroromvacroPOS-F5-001_Monitorizare_RA_rev02pdf · 33 În lipsa Responsabilului cu Farmacovigilenta sarcinile privind monitorizarea reactiilor adverse vor fi preluate src=https:reader039vdocumentecomreader039viewer20220331225e31638c7f7a9b00971bd473html5thumbnails1jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 2button div class=ts-image a href=https:reader039vdocumentecomreader039viewer20220331225e31638c7f7a9b00971bd473html5page2jpg target=_blank amp-img class=ts-thumb alt=Page 2: romvacroromvacroPOS-F5-001_Monitorizare_RA_rev02pdf · 33 În lipsa Responsabilului cu Farmacovigilenta sarcinile privind monitorizarea reactiilor adverse vor fi preluate src=https:reader039vdocumentecomreader039viewer20220331225e31638c7f7a9b00971bd473html5thumbnails2jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 3button div class=ts-image a href=https:reader039vdocumentecomreader039viewer20220331225e31638c7f7a9b00971bd473html5page3jpg target=_blank amp-img class=ts-thumb alt=Page 3: romvacroromvacroPOS-F5-001_Monitorizare_RA_rev02pdf · 33 În lipsa Responsabilului cu Farmacovigilenta sarcinile privind monitorizarea reactiilor adverse vor fi preluate src=https:reader039vdocumentecomreader039viewer20220331225e31638c7f7a9b00971bd473html5thumbnails3jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 4button div class=ts-image a href=https:reader039vdocumentecomreader039viewer20220331225e31638c7f7a9b00971bd473html5page4jpg target=_blank amp-img class=ts-thumb alt=Page 4: romvacroromvacroPOS-F5-001_Monitorizare_RA_rev02pdf · 33 În lipsa Responsabilului cu Farmacovigilenta sarcinile privind monitorizarea reactiilor adverse vor fi preluate src=https:reader039vdocumentecomreader039viewer20220331225e31638c7f7a9b00971bd473html5thumbnails4jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=ts-pagebuttonPage 5button div class=ts-image a href=https:reader039vdocumentecomreader039viewer20220331225e31638c7f7a9b00971bd473html5page5jpg target=_blank amp-img class=ts-thumb alt=Page 5: romvacroromvacroPOS-F5-001_Monitorizare_RA_rev02pdf · 33 În lipsa Responsabilului cu Farmacovigilenta sarcinile privind monitorizarea reactiilor adverse vor fi preluate src=https:reader039vdocumentecomreader039viewer20220331225e31638c7f7a9b00971bd473html5thumbnails5jpg width=142 height=106 layout=responsive amp-imga divdiv